ARID1A and non-small cell lung carcinoma: These observations merit the prospective validation of ARID1A alterations as a predictive and prognostic biomarker in patients with NSCLC, which could be helpful in refining patient stratification algorithms, along with more established markers such as PD‐L1 expression levels or TMB.